Impact Biomedical (IBO) Research & Development (2022 - 2026)

Impact Biomedical (IBO) has reported Research & Development for 5 consecutive years, with $76000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 1.33% year-over-year to $76000.0; the trailing twelve-month figure through Jun 2026 stood at $249000.0 (down 68.28% YoY), and the FY2024 full-year result was $633000.0, down 62.43% from the prior year.
• Research & Development rose to $76000.0 in Q2 2026 per IBO's latest filing, from $46000.0 in the prior quarter.
• Across five years, Research & Development topped out at $630000.0 in Q4 2023 and bottomed at $46000.0 in Q1 2026.
• Historically, Research & Development has averaged $234562.5 across 5 years, with a median of $181000.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Research & Development gained 29.13% in 2024, then slumped 88.72% in 2025.
• Over 5 years, Research & Development stood at $522000.0 in 2022, then grew by 20.69% to $630000.0 in 2023, then plunged by 76.83% to $146000.0 in 2024, then sank by 64.38% to $52000.0 in 2025, then soared by 46.15% to $76000.0 in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $76000.0, $46000.0, and $52000.0 for Q2 2026, Q1 2026, and Q3 2025 respectively.